Literature DB >> 17887730

Clustered negative charges on the lipid membrane surface induce beta-sheet formation of prion protein fragment 106-126.

Takashi Miura1, Mayumi Yoda, Naoyuki Takaku, Takanori Hirose, Hideo Takeuchi.   

Abstract

The conformational conversion of prion protein (PrP) from an alpha-helix-rich normal cellular isoform (PrPC) to a beta-sheet-rich pathogenic isoform (PrPSc) is a key event in the development of prion diseases, and it takes place in caveolae, cavelike invaginations of the plasma membrane. A peptide homologous to residues 106-126 of human PrP (PrP106-126) is known to share several properties with PrPSc, e.g., the capability to form a beta-sheet and toxicity against PrPC-expressing cells. PrP106-126 is thus expected to represent a segment of PrP that is involved in the formation of PrPSc. We have examined the effect of lipid membranes containing negatively charged ganglioside, an important component of caveolae, on the secondary structure of PrP106-126 by circular dichroism. The peptide forms an alpha-helical or a beta-sheet structure on the ganglioside-containing membranes. The beta-sheet content increases with an increase of the peptide:lipid ratio, indicating that the beta-sheet formation is linked with self-association of the positively charged peptide on the negatively charged membrane surface. Analogous beta-sheet formation is also induced by membranes composed of negatively charged and neutral glycerophospholipids with high and low melting temperatures, respectively, in which lateral phase separation and clustering of negatively charged lipids occur as shown by Raman spectroscopy. Since ganglioside-containing membranes also exhibit lateral phase separation, clustered negative charges are concluded to be responsible for the beta-sheet formation of PrP106-126. In caveolae, clustered ganglioside molecules are likely to interact with the residue 106-126 region of PrPC to promote the PrPC-to-PrPSc conversion.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17887730     DOI: 10.1021/bi700939j

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  8 in total

1.  Phospholipid composition of membranes directs prions down alternative aggregation pathways.

Authors:  Philip J Robinson; Teresa J T Pinheiro
Journal:  Biophys J       Date:  2010-04-21       Impact factor: 4.033

2.  Spectroscopic Characterization of Intermolecular Interaction of Amyloid β Promoted on GM1 Micelles.

Authors:  Maho Yagi-Utsumi; Koichi Matsuo; Katsuhiko Yanagisawa; Kunihiko Gekko; Koichi Kato
Journal:  Int J Alzheimers Dis       Date:  2010-12-28

3.  Membrane-mediated amyloid formation of PrP 106-126: A kinetic study.

Authors:  Yen Sun; Wei-Chin Hung; Ming-Tao Lee; Huey W Huang
Journal:  Biochim Biophys Acta       Date:  2015-07-26

4.  Membrane Incorporation, Channel Formation, and Disruption of Calcium Homeostasis by Alzheimer's β-Amyloid Protein.

Authors:  Masahiro Kawahara; Isao Ohtsuka; Shoko Yokoyama; Midori Kato-Negishi; Yutaka Sadakane
Journal:  Int J Alzheimers Dis       Date:  2011-04-12

5.  Liberation of GPI-anchored prion from phospholipids accelerates amyloidogenic conversion.

Authors:  Shen-Jie Lin; Kun-Hua Yu; Jhih-Ru Wu; Chin-Fa Lee; Cheng-Ping Jheng; Hau-Ren Chen; Cheng-I Lee
Journal:  Int J Mol Sci       Date:  2013-09-03       Impact factor: 5.923

Review 6.  Exploring Anti-Prion Glyco-Based and Aromatic Scaffolds: A Chemical Strategy for the Quality of Life.

Authors:  María Teresa Blázquez-Sánchez; Ana M de Matos; Amélia P Rauter
Journal:  Molecules       Date:  2017-05-24       Impact factor: 4.411

7.  Biophysical insights into how surfaces, including lipid membranes, modulate protein aggregation related to neurodegeneration.

Authors:  Kathleen A Burke; Elizabeth A Yates; Justin Legleiter
Journal:  Front Neurol       Date:  2013-03-01       Impact factor: 4.003

Review 8.  Caveolae structure and function.

Authors:  Candice M Thomas; Eric J Smart
Journal:  J Cell Mol Med       Date:  2008-02-27       Impact factor: 5.310

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.